The fifth session of the 10th general meeting of China pharmaceutical promotion association was held successfully

On September 17, 2018, the fifth meeting of the 10th general meeting of China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China pharmaceutical promotion association") was held in Suzhou, Jiangsu Province More than 250 representatives from 124 member units of China Pharmaceutical Association attended the meeting This meeting was presided over by Jiang Jiandong, President of China Association for the promotion of drugs 2017-2018 and director of Institute of medicine, Chinese Academy of Medical Sciences Jiang Jiandong, President of CFDA in 2017-2018, presided over the working conference of the general assembly, song Ruilin, executive chairman of CFDA, summarized the work of CFDA in the past year from five aspects: giving advice and suggestions to the government, publicizing China's innovation achievements through multiple channels, building a platform for pharmaceutical innovation and investment exchange, promoting innovation achievements to the international level and organizing academic conferences to serve innovation Song Ruilin, executive chairman of China Pharmaceutical Promotion Association Song Ruilin, executive chairman of CFDA, pointed out in his work report that CFDA has always been adhering to the tenet of "innovation, industrialization and internationalization", giving full play to the role of industry think tank, making suggestions and suggestions for improving the relevant policies of national health insurance and drug supervision, and actively providing construction for the establishment of dynamic adjustment mechanism of basic health insurance catalogue, anti-cancer drug medical insurance access negotiation and national drug centralized purchase pilot To accept the Commission of the former CFDA, to study and give suggestions on the implementation plan of establishing drug patent link system, carrying out patent period compensation pilot, improving China's basic drug system, etc.; to publicize China's pharmaceutical innovation through multiple channels and channels, such as cooperation with pharmaceutical economic news to carry out innovative enterprise publicity and holding "Dushu Lake Cup" pharmaceutical innovation brand selection " The new environment and achievements will focus on meeting the clinical needs, build Chinese pharmaceutical innovation brand with innovative standards, establish "China Pharmaceutical Innovation and investment conference", build a zero distance communication and dialogue platform for pharmaceutical innovation and investment community, send out the voice of China's pharmaceutical innovation industry through joint meetings with foreign organizations or attend international conferences, contribute to China's strength, and improve innovation and R & D Ability: held various academic conferences, including hospital pharmacy policy forum and GCP related conferences, to promote the continuous improvement of clinical research quality and pharmaceutical service level in China President Song pointed out that in the future, CFDA will continue to play the role of industry think tank team, carry out research and formulation of policies and industry guidelines, and promote the implementation of reform measures as soon as possible; establish innovative R & D cooperation mechanism with relevant institutions at home and abroad to jointly promote the improvement of China's drug innovation level and international integration; launch the establishment of pharmaceutical innovation development foundation for Chinese Medicine Pharmaceutical innovation provides financial support; establishes a new working group to prepare for the new election; continues to build a diversified international exchange platform covering the whole process, and runs the fourth Investment Conference; continues to run the 2019 "Dushu Lake Cup" pharmaceutical innovation brand selection activity in accordance with the new model of pharmaceutical innovation brand selection; establishes the "China rare diseases alliance" to integrate the rare diseases fund in China To further improve the level of diagnosis and treatment of rare diseases; to enrich the membership structure, strengthen capacity-building, run various academic conferences, and provide more innovative and diversified services for member units The meeting deliberated and passed the 2017-2018 annual work report of China pharmaceutical innovation promotion association, 2017-2018 annual dues income and expenditure report of China pharmaceutical innovation promotion association, proposal on developing member units of China pharmaceutical innovation promotion association, ethical guidelines for pharmaceutical enterprises of China pharmaceutical innovation promotion association, proposal on establishing a new election preparatory working group By secret ballot, the proposal on the standard of membership fee ratification was adopted The meeting also deliberated and approved the application for admission of four units, including Tianjing Biotechnology (Shanghai) Co., Ltd., Beijing Spring Pharmaceutical Technology Development Co., Ltd., Guotai Junan Securities Co., Ltd and Guoshou Equity Investment Co., Ltd At the end of the working session, Jiang Jiandong, President of CFDA in 2017-2018, issued an honorary certificate to Liu Dianbo, President of CFDA in 2018-2019 Liu Dianbo, the new president, made a speech, and Liu Dianbo, the new president, affirmed the work of the previous year of China Association for the promotion of drugs, and put forward the ideas and requirements for the work of the next year He said that in the next year, he will work with colleagues to seek opportunities to meet challenges and make the pharmaceutical industry better The general meeting is rich in content, compact in arrangement and successfully completed various agendas Through various agendas such as the ratification of membership fee standard, the establishment of ethical standards and the establishment of a new election working group, the internal governance structure has been improved, laying the foundation for the determination of development direction and the implementation of main tasks in the next year; at the same time, the addition of new members has injected new blood and power into the promotion of pharmaceutical innovation and development of China Pharmaceutical Association, highlighting the promotion of pharmaceutical innovation of China Pharmaceutical Association The expansion of fields and the further enhancement of cohesion Meeting place